Fibroblast growth factor receptors in breast cancer: Expression, downstream effects, and possible drug targets

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages

  Tenhagen, M ^a   Van Diest, P J ^a   Ivanova, I A ^a   Van Der Wall, E ^a   Van Der Groep, P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AFIMOXIFENE; ANTINEOPLASTIC AGENT; AZD 4547; BGJ 398; BRIVANIB ALANINATE; CYCLOPHOSPHAMIDE; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FP 1039; ILOMASTAT; INTERLEUKIN 1BETA; KI 67 ANTIGEN; NINTEDANIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; RABEPRAZOLE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHROMOGENIC IN SITU HYBRIDIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DISTANT METASTASIS; DRUG EFFICACY; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MISSENSE MUTATION; MOLECULAR DYNAMICS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; DRUG DISCOVERY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, FIBROBLAST GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84864401436     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0060     Document Type: Review

References (90)

1. Acevedo VD, Ittmann M & Spencer DM 2009 Paths of FGFR-driven tumorigenesis. Cell Cycle 8 580-588. (doi:10.4161/cc.8.4.7657)
2. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D et al. 2007 Integrated profiling of basal and luminal breast cancers. Cancer Research 67 11565-11575. (doi:10.1158/0008-5472.CAN-07-2536)
3. Alvarez RH, Valero V & Hortobagyi GN 2010 Emerging targeted therapies for breast cancer. Journal of Clinical Oncology 28 3366-3379. (doi:10.1200/JCO.2009.25.4011)
4. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G et al. 2009 Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clinical Cancer Research 15 441-451. (doi:10.1158/1078-0432.CCR-08-1791)
5. Andre F, Bachelot D, CamponeM, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner NC, Rugo HS, ShiMM, Zhang Y et al. 2011 A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. Journal of Clinical Oncology 29 S508. (doi:10.1200/JCO.2010.31.6877)
6. Antoniu SA & Kolb MR 2010 Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs: the Investigational Drugs Journal 13 332-345.
7. Arteaga CL 2003 Inhibiting tyrosine kinases: successes and limitations. Cancer Biology & Therapy 2 S79-S83.
8. Bane AL, Pinnaduwage D, Colby S, Bull SB, O'Malley FP &Andrulis IL 2009 Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Research and Treatment 117 183-191. (doi:10.1007/s10549-008-0087-1)
9. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I et al. 2002 Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Research 62 840-847.
10. Beenken A & Mohammadi M 2009 The FGF family: biology, pathophysiology and therapy. Nature Reviews. Drug Discovery 8 235-253. (doi:10.1038/nrd2792)
11. Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, Serra SC, D'Incalci M, Cavalletti E, Giavazzi R et al. 2011 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Research 71 1396-1405. (doi:10.1158/0008-5472.CAN-10- 2700)
12. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F &Delattre O 2008 Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Research 68 7165-7175. (doi:10.1158/0008-5472.CAN-08-1360)
13. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A et al. 2006 Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 353-357. (doi:10.1038/nature04296)
14. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP & Radvanyi F 1999 Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics 23 18-20. (doi:10.1038/12615)
15. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall G et al. 2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289-1297. (doi:10.1038/ng1901)
16. Chin K, De Vries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T et al. 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 529-541. (doi:10.1016/j.ccr.2006.10.009)
17. Cohen MS, Zhang C, Shokat KM & Taunton J 2005 Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308 1318-1321. (doi:10.1126/science1108367)
18. Dailey L, Ambrosetti D, Mansukhani A & Basilico C 2005 Mechanisms underlying differential responses to FGF signaling. Cytokine & Growth Factor Reviews 16 233-247. (doi:10.1016/j.cytogfr.2005.01.007)
19. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R et al. 2007 Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 1087-1093. (doi:10.1038/nature05887)
20. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO & Reis-Filho JS 2007 FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Research 9 R23. (doi:10.1186/bcr1665)
21. Eswarakumar VP, Lax I & Schlessinger J 2005 Cellular signaling by fibroblast growth factor receptors. Cytokine & Growth Factor Reviews 16 139-149. (doi:10.1016/j.cytogfr.2005.01.001)
22. Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM 2008 Globocan 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Available from: http://globocan.iarc.fr accessed on 20/10/2010.
23. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM & Spencer DM 2003 Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Research 63 8256-8263.
24. Fremin C & Meloche S 2010 From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Journal of Hematology & Oncology 3 8. (doi:10.1186/1756-8722-3-8)
25. Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, Ozdag H, Vias M, Kranjac T, Subkhankulova T, Paish C et al. 2005 A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 24 5235-5245. (doi:10.1038/sj.onc.1208741)
26. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI et al. 2008 Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genetics 4 e1000054. (doi:10.1371/journal. pgen.1000054)
27. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F et al. 2005 Comprehensive profiling of 8p11-12 amplification in breast cancer. Molecular Cancer Research 3 655-667. (doi:10.1158/1541-7786.MCR-05-0128)
28. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al. 2007 Patterns of somatic mutation in human cancer genomes. Nature 446 153-158. (doi:10.1038/nature05610)
29. Hafner C, Vogt T & Hartmann A 2006 FGFR3 mutations in benign skin tumors. Cell Cycle 5 2723-2728. (doi:10.4161/cc.5.23.3509)
30. Harmer NJ, Ilag LL, Mulloy B, Pellegrini L, Robinson CV &Blundell TL 2004 Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. Journal of Molecular Biology 339 821-834. (doi:10.1016/j.jmb.2004.04.031)
31. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al. 2008 BIF1120: a tripple angiokinase inhibitor with sustained receptor bockade and good antitumor efficacy. Cancer Research 68 4774-4782. (doi:10.1158/0008-5472.CAN-07- 6307)
32. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A et al. 2007 A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 39 870-874. (doi:10.1038/ng2075)
33. Ireson CR & Kelland LR 2006 Discovery and development of anticancer aptamers. Molecular Cancer Therapeutics 5 2957-2962. (doi:10.1158/1535-7163.MCT- 06-0172)
34. Jaakkola S, Salmikangas P,Nylund S, Partanen J,Armstrong E, Pyrhonen S, Lehtovirta P & Nevanlinna H 1993 Amplification of fgfr4 gene in human breast and gynecological cancers. International Journal of Cancer 54 378-382. (doi:10.1002/ijc.2910540305)
35. Jemal A, Center MM, DeSantis C & Ward EM 2010 Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers &Prevention 19 1893-1907. (doi:10.1158/1055-9965.EPI-10-0437)
36. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P &Ricolleau G 2004 G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. British Journal of Cancer 90 189-193. (doi:10.1038/sj.bjc.6601450)
37. Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T et al. 2009 Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Research 69 7357-7365. (doi:10.1158/0008-5472.CAN-09-0064)
38. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J et al. 2010 Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466 869-873. (doi:10.1038/ nature09208)
39. Kang MH & Reynolds CP 2009 Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 15 1126-1132. (doi:10.1158/1078-0432.CCR-08-0144)
40. Katoh Y & Katoh M 2009 FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review). International Journal of Molecular Medicine 23 307-311.
41. Keer H 2010 Safety study of FP1039 to treat cancer, Five Prime Therapeutics Inc and Parexel, Clinicaltrials.gov identifier: NCT00687505.
42. Koziczak M, Holbro T & Hynes NE 2004 Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23 3501-3508. (doi:10.1038/sj.onc.1207331)
43. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW et al. 2006 Regulation of fibroblast growth factor-23 signaling by klotho. Journal of Biological Chemistry 281 6120-6123. (doi:10.1074/jbc.C500457200)
44. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD & Knowles MA 2011 Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. British Journal of Cancer 104 75-82. (doi:10.1038/sj.bjc.6606016)
45. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C et al. 2006 Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6 245. (doi:10.1186/1471-2407-6-245)
46. Li S, Christensen C, Kiselyov VV, Kohler LB, Bock E &Berezin V 2008 Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. Journal of Neurochemistry 104 667-682. (doi:10.1111/j.1471-4159.2007.05070.x)
47. Lintermans A, Neven P & Paridaens R 2011 Drug safety evaluation of exemestane. Expert Opinion on Drug Safety 10 473-487. (doi:10.1517/14740338. 2011.567264)
48. Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S et al. 2008 Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. Journal of Pathology 215 398-410. (doi:10.1002/path.2368)
49. Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P, Hahn M & Schneeweiss A 2010 FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Annals of Oncology 21 1636-1642. (doi:10.1093/annonc/mdq017)
50. Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA & Dorssers LC 2008 Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocrine-Related Cancer 15 101-111. (doi:10.1677/ERC-07-0080)
51. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C & Ponder BA 2008 Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biology 6 e108. (doi:10.1371/journal.pbio.0060108)
52. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R &van Diest PJ 2010 Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Modern Pathology 23 1029-1039. (doi:10.1038/modpathol.2010.84)
53. Mohammadi M, Olsen SK & Ibrahimi OA 2005 Structural basis for fibroblast growth factor receptor activation. Cytokine & Growth Factor Reviews 16 107-137. (doi:10.1016/j.cytogfr.2005.01.008)
54. Mukai H 2010 Targeted therapy in breast cancer: current status and future directions. Japanese Journal of Clinical Oncology 40 711-716. (doi:10.1093/jjco/hyq037)
55. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D & deLapeyriere O 1995 Expression of FGF and FGF receptor genes in human breast cancer. International Journal of Cancer 61 170-176. (doi:10.1002/ijc.2910610205)
56. Peterson C 2011 Drug therapy of cancer. European Journal of Clinical Pharmacology 67 437-447. (doi:10.1007/s00228-011-1011-x)
57. Petrelli A & Giordano S 2008 From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Current Medicinal Chemistry 15 422-432. (doi:10.2174/092986708783503212)
58. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ et al. 2010 Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in themouse mammary tumor virus - Wnt-1 mouse model of breast cancer. Cancer Research 70 4868-4879. (doi:10.1158/0008-5472.CAN-09-4404)
59. Prosnitz LR, Iglehart JD & Winer EP 2001 Chapter 17: breast cancer. In Clinical Oncology: A Multi-disciplinary Approach for Physicians and Students, 8th edn, pp 267-273. Eds P Rubin & JP Williams. Waltham, MA, USA: Elsevier health sciences.
60. Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA & Ethier SP 2004 Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Research 64 40-47. (doi:10.1158/0008-5472.CAN- 03-1022)
61. Reed JR, Leon RP, Hall MK & Schwertfeger KL 2009 Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Research 11 R21. (doi:10.1186/bcr2246)
62. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T et al. 2006 FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clinical Cancer Research 12 6652-6662. (doi:10.1158/1078-0432.CCR-06-1164)
63. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P &Ullrich A 2009 Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clinical Cancer Research 15 2058-2066. (doi:10.1158/1078-0432. CCR-08-0890)
64. Sahlin P, Tarnow P, Martinsson T & Stenman G 2009 Germline mutation in the FGFR3 gene in a TWIST1-negative family with Saethre-Chotzen syndrome and breast cancer. Genes, Chromosomes & Cancer 48 285-288. (doi:10.1002/gcc. 20637)
65. Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA & Rosen JM 2006 A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Research 66 5676-5685. (doi:10.1158/0008-5472. CAN-05-3781)
66. Seitzer N, Mayr T, Streit S & Ullrich A 2010 A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Research 70 802-812. (doi:10.1158/0008-5472.CAN-09-3239)
67. Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F & Pusztai L 2010 Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Research and Treatment 123 747-755. (doi:10.1007/s10549-009-0677-6)
68. Sibley K, Stern P & Knowles MA 2001 Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20 4416-4418. (doi:10.1038/sj.onc.1204543)
69. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N et al. 2006 The consensus coding sequence of human breast and colorectal cancers. Science 314 268-274. (doi:10.1126/science. 1133427)
70. Stadler CR, Knyazev P, Bange J & Ullrich A 2006 FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cellular Signalling 18 783-794. (doi:10.1016/j.cellsig.2005.07.002)
71. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C et al. 2005 A screen of the complete protein kinase gene family identifies diverse patterns of somatic muations in human breast cancer. Nature Genetics 37 590-592. (doi:10.1038/ng1571)
72. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J, Lehti K et al. 2010a FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. PNAS 107 15786-15791. (doi:10.1073/pnas.0914459107)
73. Sugiyama N, Varjosalo M, Meller P, Lohi J, Hyytiainen M, Kilpinen S, Kallioniemi O, Ingvarsen S, Engelholm LH, Taipale J et al. 2010b Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Research 80 7851-7861. (doi:10.1158/0008-5472.CAN-10-1223)
74. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, Liang X, Sun Q & Pang D 2011 Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. Journal of Surgical Oncology 105 773-779. (doi:10.1002/jso.22120)
75. Tomlinson D, Knowles M & Speirs V 2012 Mechanisms of FGFR3 actions in endocrine resistant breast cancer. International Journal of Cancer 130 2857-2866. (doi:10.1002/ijc.26304)
76. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A et al. 2006 FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. Journal of Clinical Oncology 24 3747-3755. (doi:10.1200/JCO.2005.04.8587)
77. Turner N & Grose R 2010 Fibroblast growth factor signalling: from development to cancer. Nature Reviews. Cancer 10 116-129. (doi:10.1038/nrc2780)
78. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A et al. 2010a Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29 2013-2023. (doi:10.1038/onc.2009.489)
79. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A et al. 2010b FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research 70 2085-2094. (doi:10.1158/0008-5472.CAN-09-3746)
80. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG & Alitalo K 1994 Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. Journal of Biological Chemistry 269 18320-18326.
81. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM & Rosen JM 2002 Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. Journal of Cell Biology 157 703-714. (doi:10.1083/jcb.200107119)
82. Whitley BR, Palmieri D, Twerdi CD & Church FC 2004 Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Experimental Cell Research 296 151-162. (doi:10.1016/j.yexcr.2004.02.022)
83. Wu DQ, Kan MK, Sato GH, Okamoto T & Sato JD 1991 Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. Journal of Biological Chemistry 266 16778-16785.
84. Xian W, Schwertfeger KL, Vargo-Gogola T & Rosen JM 2005 Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. Journal of Cell Biology 171 663-673. (doi:10.1083/jcb. 200505098)
85. Xian W, Schwertfeger KL & Rosen JM 2007 Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Molecular Endocrinology 21 987-1000. (doi:10.1210/me.2006-0518)
86. Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM & Brugge JS 2009 Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Research 69 2244-2251. (doi:10.1158/0008-5472.CAN-08-3398)
87. Yang ZQ, Streicher KL, Ray ME, Abrams J & Ethier SP 2006 Multiple interacting oncogenes on the 8p11-12 amplicon in human breast cancer. Cancer Research 66 11632-11643. (doi:10.1158/0008-5472.CAN-06-2946)
88. Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, Toratani S, Kan M, Sato JD & Okamoto T 2005 Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. International Journal of Cancer 117 166-168. (doi:10.1002/ijc.21145)
89. Zhang H, Masuoka LB, Sadra AB, Brennan T, Doberstein S, Goodworth G, Hestir K, Hollenbaugh D, Long L, Qin M, et al. 2007 LT FP-1039 (FGFR1:Fc), A soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. AACR-NCI-ERTC International Conference, San Francisco.
90. Zhu X, Asa SL & Ezzat S 2009 Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Molecular Endocrinology 23 1397-1405. (doi:10.1210/me.2009-0071)